Skip to main content
Midas Edge

PLIANT THERAPEUTICS, INC.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

PLRX$0.79-1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Statements of Stockholders’ Equity (Unaudited

Condensed Statements of Stockholders’ Equity

AdditionalPaid-InCapital · AccumulatedOtherComprehensive Gain/(Loss) · AccumulatedDeficit · TotalStockholders’Equity
Common Stock
Shares · Amount
Balance at December 31, 202460,860,838$6$1,013,806$321$(710,052)$304,081
Issuance of common stock under benefit plans525,345—498——498
Stock-based compensation expense——8,913——8,913
Net unrealized loss on short-term investments———(162)—(162)
Net loss————(56,166)(56,166)
Balance at March 31, 202561,386,183$6$1,023,217$159$(766,218)$257,164
Issuance of common stock under benefit plans——————
Stock-based compensation expense——6,378——6,378
Net unrealized loss on short-term investments———(160)—(160)
Net loss————(43,300)(43,300)
Balance at June 30, 202561,386,183$6$1,029,595$(1)$(809,518)$220,082
Issuance of common stock under benefit plans63,107—72——72
Stock-based compensation expense——6,418——6,418
Net unrealized gain on short-term investments———35—35
Net loss————(26,301)(26,301)
Balance at September 30, 202561,449,290$6$1,036,085$34$(835,819)$200,306

Condensed Statements of Stockholders’ Equity

AdditionalPaid-InCapital · AccumulatedOtherComprehensive Loss · AccumulatedDeficit · TotalStockholders’Equity
Common Stock
Shares · Amount
Balance at December 31, 202359,921,002$6$972,973$345$(499,748)$473,576
Issuance of common stock under benefit plans397,540—1,879——1,879
Stock-based compensation expense——9,666——9,666
Net unrealized loss on short-term investments———(834)—(834)
Net loss————(46,955)(46,955)
Balance at March 31, 202460,318,542$6$984,518$(489)$(546,703)$437,332
Issuance of common stock under benefit plans106,602—684——684
Stock-based compensation expense——10,644——10,644
Net unrealized loss on short-term investments———(128)—(128)
Net loss————(55,854)(55,854)
Balance at June 30, 202460,425,144$6$995,846$(617)$(602,557)$392,678
Issuance of common stock under benefit plans424,359—543——543
Stock-based compensation expense——8,899——8,899
Net unrealized gain on short-term investments———1,465—1,465
Net loss————(57,763)(57,763)
Balance at September 30, 202460,849,503$6$1,005,288$848$(660,320)$345,822
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.